atl1102 a clear winner, page-30

Let's just talk about ATL1102 for Stem Cells Mobilisation for now.

If it is an approved compound, its sales is $200m per annum until 2031 (US patent pending) or roughly $3 billion worth of sales starting from 2016.

So from Phase 1 to marketing approval, we have a gap of 2cps (MC $20m) and $3 (MC $3b) per share to be filled in the next 3 years.

If we use an oil exploration company like WHN to illustrate the point. WHN has an MC of $50m (went as high as 70m in Nov 2011)for a completed 2D seismic work. (equivalent to an IND (investigative new drug) approval status in Biotech term) Yet ANP is lingering around MC of $20m.

So, the current SP of ANP is probably a reflection of ASX being a Mining and Oil centric market.


May be this article on Four Events that can Trigger a Biotech Stock Re-rating may show that ANP has ticked all the boxes on the re-rating events suggested,
regardless of how the local market is treating it at the moment.

JIMO




cheers